CD274 and neoplasm: Biomarker discovery remains a focal point for research, enabling the identification of novel molecular targets and the development of companion diagnostics.141 Recent studies have highlighted promising biomarkers like PD-L1 and TILs (Tumor-Infiltrating Lymphocytes) as indicators of immunotherapy response.142